1
|
García-Recio E, Costela-Ruiz VJ, Illescas-Montes R, Melguizo-Rodríguez L, García-Martínez O, Ruiz C, De Luna-Bertos E. Modulation of Osteogenic Gene Expression by Human Osteoblasts Cultured in the Presence of Bisphenols BPF, BPS, or BPAF. Int J Mol Sci 2023; 24:ijms24054256. [PMID: 36901687 PMCID: PMC10002049 DOI: 10.3390/ijms24054256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 01/26/2023] [Accepted: 02/16/2023] [Indexed: 02/23/2023] Open
Abstract
Bone effects attributed to bisphenols (BPs) include the inhibition of growth and differentiation. This study analyzes the effect of BPA analogs (BPS, BPF, and BPAF) on the gene expression of the osteogenic markers RUNX2, osterix (OSX), bone morphogenetic protein-2 (BMP-2), BMP-7, alkaline phosphatase (ALP), collagen-1 (COL-1), and osteocalcin (OSC). Human osteoblasts were obtained by primary culture from bone chips harvested during routine dental work in healthy volunteers and were treated with BPF, BPS, or BPAF for 24 h at doses of 10-5, 10-6, and 10-7 M. Untreated cells were used as controls. Real-time PCR was used to determine the expression of the osteogenic marker genes RUNX2, OSX, BMP-2, BMP-7, ALP, COL-1, and OSC. The expression of all studied markers was inhibited in the presence of each analog; some markers (COL-1; OSC, BMP2) were inhibited at all three doses and others only at the highest doses (10-5 and 10-6 M). Results obtained for the gene expression of osteogenic markers reveal an adverse effect of BPA analogs (BPF, BPS, and BPAF) on the physiology of human osteoblasts. The impact on ALP, COL-1, and OSC synthesis and therefore on bone matrix formation and mineralization is similar to that observed after exposure to BPA. Further research is warranted to determine the possible contribution of BP exposure to the development of bone diseases such as osteoporosis.
Collapse
Affiliation(s)
- Enrique García-Recio
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain
- Institute of Biosanitary Research, ibs.GRANADA, Avda. de Madrid, 15 Pabellón de Consultas Externas, 2a Planta, 18012 Granada, Spain
| | - Víctor J. Costela-Ruiz
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain
- Institute of Biosanitary Research, ibs.GRANADA, Avda. de Madrid, 15 Pabellón de Consultas Externas, 2a Planta, 18012 Granada, Spain
| | - Rebeca Illescas-Montes
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain
- Institute of Biosanitary Research, ibs.GRANADA, Avda. de Madrid, 15 Pabellón de Consultas Externas, 2a Planta, 18012 Granada, Spain
| | - Lucía Melguizo-Rodríguez
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain
- Institute of Biosanitary Research, ibs.GRANADA, Avda. de Madrid, 15 Pabellón de Consultas Externas, 2a Planta, 18012 Granada, Spain
| | - Olga García-Martínez
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain
- Institute of Biosanitary Research, ibs.GRANADA, Avda. de Madrid, 15 Pabellón de Consultas Externas, 2a Planta, 18012 Granada, Spain
| | - Concepción Ruiz
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain
- Institute of Biosanitary Research, ibs.GRANADA, Avda. de Madrid, 15 Pabellón de Consultas Externas, 2a Planta, 18012 Granada, Spain
- Institute of Neuroscience, University of Granada, 18016 Granada, Spain
- Correspondence: ; Tel.: +34-958-243-497
| | - Elvira De Luna-Bertos
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, Avda. Ilustración 60, 18016 Granada, Spain
- Institute of Biosanitary Research, ibs.GRANADA, Avda. de Madrid, 15 Pabellón de Consultas Externas, 2a Planta, 18012 Granada, Spain
| |
Collapse
|
2
|
Lehmann TP, Iwańczyk-Skalska E, Harasymczuk J, Jagodziński PP, Głowacki M. Gene Expression in MC3T3-E1 Cells Treated with Diclofenac and Methylprednisolone. Genes (Basel) 2023; 14:genes14010184. [PMID: 36672925 PMCID: PMC9859560 DOI: 10.3390/genes14010184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 12/26/2022] [Accepted: 01/05/2023] [Indexed: 01/13/2023] Open
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids (GCs) are often used to treat articular-skeletal disorders. The extended use of NSAIDs and GCs have adverse effects on bone metabolism, reducing bone quality and impairing fracture healing. In the present study, we used mouse pre-osteoblast cells MC3T3-E1 to demonstrate the effects of diclofenac (DF) and methylprednisolone (MP) on cell proliferation and gene expression. Cells were incubated with three doses of DF or MP: 0.5 µM, 5 µM, and 50 µM. MP decreased cell viability even after 24 h, but DF inhibited cell viability after only seven days of treatment. The cells were lysed after one, two, three, and seven days of treatment, and gene expression was analyzed by reverse transcription and quantitative PCR (RT-qPCR) assays. DF did not significantly affect the expression of the osteogenic marker genes. MP modified the expression of Osx, Runx, and Col1a1. We concluded that MP is a more potent inhibitor of mouse pre-osteoblast differentiation and viability than is DF. Our results suggest that prolonged DF treatment could be less harmful to osteoblasts than MP treatment.
Collapse
Affiliation(s)
- Tomasz P. Lehmann
- Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Święcickiego 6, 60-781 Poznan, Poland
- Correspondence: ; Tel.: +48-618-546-513; Fax: +48-618-546-510
| | - Ewa Iwańczyk-Skalska
- Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Święcickiego 6, 60-781 Poznan, Poland
| | - Jerzy Harasymczuk
- Department of Paediatric Surgery, Traumatology and Urology, Poznan University of Medical Sciences, Szpitalna 27/33, 60-572 Poznan, Poland
| | - Paweł P. Jagodziński
- Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Święcickiego 6, 60-781 Poznan, Poland
| | - Maciej Głowacki
- Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences, 28 Czerwca 1956 135/147, 61-545 Poznan, Poland
| |
Collapse
|
3
|
Hadjicharalambous C, Alpantaki K, Chatzinikolaidou M. Effects of NSAIDs on pre-osteoblast viability and osteogenic differentiation. Exp Ther Med 2021; 22:740. [PMID: 34046094 DOI: 10.3892/etm.2021.10172] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Accepted: 10/28/2020] [Indexed: 12/13/2022] Open
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of a variety of musculoskeletal conditions, injuries and after surgery for postoperative pain management. Their use has been associated with impaired bone healing, possibly due to a multifactorial function, which may include inhibition of osteoblast recruitment and differentiation. However, up to date, there is no consensus regarding the impact of NSAIDs on bone-healing. The aim of the current study was to investigate the effects of five NSAIDs on the cellular functions of mouse MC3T3-E1 pre-osteoblasts. Cells were treated with the non-selective COX inhibitors lornoxicam and diclofenac, the COX-2 selective inhibitors parecoxib, meloxicam and paracetamol, as well as steroidal prednisolone at different doses and exposure times. The PrestoBlue™ technique was used to measure cell viability, an enzymatic assay was employed for alkaline phosphatase (ALP) activity and alizarin red S mineral staining was used to determine osteogenic differentiation. All drugs had a negative impact on pre-osteoblast cell growth, with the exception of paracetamol. Lornoxicam, diclofenac and meloxicam reduced ALP activity, while the other NSAIDs had no effect and prednisolone strongly increased ALP activity. In contrast, calcium deposits were either unaffected or increased by NSAID treatments but were significantly decreased by prednisolone. These results provide evidence that NSAIDs may adversely affect the viability of mouse pre-osteoblast cells but their actions on the osteogenic differentiation are drug-specific. The direct comparison of the effects of different NSAIDs and prednisolone on pre-osteoblasts may serve to place some NSAIDs in a preferential position for analgesic and anti-inflammatory therapy during bone repair.
Collapse
Affiliation(s)
- Chrystalleni Hadjicharalambous
- Department of Materials Science and Technology, University of Crete, Heraklion 70013, Greece.,Department of Chemistry, University of Crete, Heraklion 70013, Greece
| | - Kalliopi Alpantaki
- Department of Orthopedics and Trauma, Venizeleion General Hospital of Heraklion, Heraklion 71409, Greece
| | - Maria Chatzinikolaidou
- Department of Materials Science and Technology, University of Crete, Heraklion 70013, Greece.,Institute of Electronic Structure and Laser (IESL), Foundation for Research and Technology Hellas (FORTH), Heraklion 70013, Greece
| |
Collapse
|
4
|
Macroporous scaffold surface modified with biological macromolecules and piroxicam-loaded gelatin nanofibers toward meniscus cartilage repair. Int J Biol Macromol 2021; 183:1327-1345. [PMID: 33932422 DOI: 10.1016/j.ijbiomac.2021.04.151] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Revised: 04/21/2021] [Accepted: 04/24/2021] [Indexed: 12/15/2022]
Abstract
Meniscus cartilage has poor self-healing capacity in the inner zone and its damage leads to articular cartilage degeneration. Here we have developed hybrid constructs using polycaprolactone (PCL) and polyurethane (PU) surface modified by gelatin (G), chitosan (C), and hyaluronic acid (H) biomacromolecules and piroxicam-loaded gelatin nanofibers (PCL/PU/GCH/P). The surface of constructs was crosslinked using EDC and NHS. The scaffolds were investigated by SEM, FTIR spectroscopy, swelling test, degradation rate, mechanical tests, and in vitro piroxicam release assay. Furthermore, the cell-seeded scaffolds were evaluated by SEM, viability assay, dapi staining, cell migration, proliferation, and gene expression of chondrocytes within these scaffolds. Finally, the animal study was performed in a rabbit model. Chondrocyte and rabbit adipose-derived mesenchymal stem cells (ASCs) from the infrapatellar fat pad (Hoffa's fat pad) were used. Swelling and degradation rate were increased in the modified scaffolds. Tensile and compressive Young's modulus also were near to human native meniscus tissue. The highest expression level of chondrocyte marker genes was observed for the PCL/PU/GCH scaffold. A significant regeneration was obtained in rabbits treated with ASCs-loaded PCL/PU/GCH/P scaffold after 3 months. The surface-modified scaffolds with or without ASCs could successfully accelerate meniscus regeneration and exhibit potential application in meniscus tissue engineering.
Collapse
|
5
|
Ahmad V. Prospective of extracellular matrix and drug correlations in disease management. Asian J Pharm Sci 2020; 16:147-160. [PMID: 33995610 PMCID: PMC8105415 DOI: 10.1016/j.ajps.2020.06.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 04/20/2020] [Accepted: 06/22/2020] [Indexed: 12/30/2022] Open
Abstract
The extracellular matrix (ECM) comprises of many structural molecules that constitute the extracellular environment. ECM molecules are characterized by specific features like diversity, complexity and signaling, which are also results of improvement or development of disease mediated by some physiological changes. Several drugs have also been used to manage diseases and they have been reported to modulate ECM assembly, including physiological changes, beyond their primary targets and ECM metabolism. This review highlights the alteration of ECM environment for diseases and effect of different classes of drugs like nonsteroidal anti-inflammatory drugs, immune suppressant drug, steroids on ECM or its components. Thus, it is summarized from previously conducted researches that diseases can be managed by targeting specific components of ECM which are involved in the pathophysiology of diseases. Moreover, the drug delivery focused on targeting the ECM components also has the potential for the discovery of targeted and site specific release of drugs. Therefore, ECM or its components could be future targets for the development of new drugs for controlling various disease conditions including neurodegenerative diseases and cancers.
Collapse
Affiliation(s)
- Varish Ahmad
- Health Information Technology Department, Faculty of Applied Studies, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia
| |
Collapse
|
6
|
Costela-Ruiz VJ, Melguizo-Rodríguez L, Illescas-Montes R, Ramos-Torrecillas J, Manzano-Moreno FJ, Ruiz C, Bertos EDL. Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts. Int J Med Sci 2019; 16:1466-1472. [PMID: 31673238 PMCID: PMC6818209 DOI: 10.7150/ijms.37857] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Accepted: 08/13/2019] [Indexed: 12/15/2022] Open
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2)-selective NSAIDs, are associated with adverse effects on bone tissue. These drugs are frequently the treatment of choice but are the least studied with respect to their repercussion on bone. The objective of this study was to determine the effects of celecoxib on cultured human osteoblasts. Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at doses of 0.75, 2, or 5μM for 24 h. The MTT technique was used to determine the effect on proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; and real-time polymerase chain reaction to measure the effect on gene expressions of the differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX). Therapeutic doses of celecoxib had no effect on osteoblast cell growth or antigen expression but had a negative impact on the gene expression of RUNX2 and OSC, although there was no significant change in the expression of ALP and OSX. Celecoxib at therapeutic doses has no apparent adverse effects on cultured human osteoblasts and only inhibits the expression of some differentiation markers. These characteristics may place this drug in a preferential position among NSAIDs used for analgesic and anti-inflammatory therapy during bone tissue repair.
Collapse
Affiliation(s)
- Víctor J. Costela-Ruiz
- Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain
- Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain
| | - Lucia Melguizo-Rodríguez
- Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain
- Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain
| | - Rebeca Illescas-Montes
- Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain
- Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain
| | - Javier Ramos-Torrecillas
- Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain
- Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain
| | - Francisco J. Manzano-Moreno
- Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain
- Biomedical Group (BIO277). Department of Stomatology, School of Dentistry, University of Granada, Colegio Máximo, Campus Universitario de Cartuja 18071. Granada, Spain
| | - Concepción Ruiz
- Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain
- Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain
- Institute of Neuroscience, University of Granada, Centro de Investigación Biomédica (CIBM). Parque de Tecnológico de la Salud (PTS) Avda. del Conocimiento S/N, 18016. Armilla, Granada, Spain
| | - Elvira De Luna- Bertos
- Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain
- Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain
| |
Collapse
|